Form 4: Zimmer Biomet Executive Rachel Ellingson Reports Stock Transactions

Rachel Ellingson, Chief Administrative Officer of Zimmer Biomet, reports the vesting and subsequent transactions involving restricted stock units and common stock.

Summary

• On February 18, 2025, Rachel Ellingson, Chief Administrative Officer of Zimmer Biomet Holdings, Inc., reported transactions involving common stock and restricted stock units (RSUs).
• Ellingson acquired 5,572 shares of common stock upon the vesting of RSUs on February 18, 2025.
• Simultaneously, 5,572 shares were acquired through the vesting of restricted stock units at a price of $0.
• 1,792 shares were withheld by the company to satisfy tax obligations related to the vesting of the RSUs at a price of $101.
• Ellingson also acquired 205 shares under the Employee Stock Purchase Plan on February 18, 2025.
• Following these transactions, Ellingson directly owns 10,831 shares of common stock and 5,572 restricted stock units.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The vesting of RSUs suggests that performance targets were met, which is a positive indicator. However, the document primarily reflects routine transactions.

Positives

• The vesting of RSUs indicates that performance conditions were met, suggesting positive performance over the 2022-2024 period.
• Participation in the Employee Stock Purchase Plan shows confidence in the company's future.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting of RSUs based on performance suggests an expectation of continued positive performance.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies and are closely monitored by investors for insights into management's confidence in the company's prospects. This filing is a routine disclosure required by the SEC.

Comparison to Industry Standards

• Executive compensation packages, including RSUs, are standard practice in the medical device industry, with companies like Medtronic, Stryker, and Johnson & Johnson also utilizing similar equity-based compensation strategies.
• The vesting of RSUs based on performance metrics is a common way to align executive incentives with shareholder value creation, similar to practices observed in comparable companies.

Stakeholder Impact

• The vesting of RSUs aligns executive interests with shareholder value, potentially benefiting shareholders.
• The transactions have a minimal direct impact on employees, customers, suppliers, and creditors.

Key Dates

Keywords

Zimmer Biomet, Ellingson, Stock Transactions, RSUs, Form 4, Beneficial Ownership, Executive Compensation